In our total project portfolio, we currently have six projects: five drug candidates and a product series in cosmetic dermatology. What the projects have in common is that they are based on two unique validated technology platforms that are based on solid research and collaborations with pioneering and internationally recognized researchers and academics.
The cPLA2α technology consists of a series of proprietary small molecule inhibitors of the cytosolic phospholipase A2 (cPLA2α) enzyme involved in inflammation and uncontrolled cell growth. This provides a range of potentially attractive indications for the patented molecular inhibitors of cPLA2α including skin, cancer, liver and kidney diseases.
The technology comes primarily from the Norwegian University of Science and Technology (NTNU).
The FOL peptide technology consists of a series of patented tissue-protective peptides ("small proteins") that are based on a modified part of the natural human protein osteopontin. Osteopontin is a glycoprotein expressed in many types of tissues, including the hair follicle and bone, and plays a key role in cell stimulation processes.
The technology comes primarily from Lund University in Sweden.